Phase 4 COMPARE trial data show Nuvaxovid was associated with lower reactogenicity and fewer daily activity disruptions than mNEXSPIKE.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results